S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$11.45
+0.04 (+0.35%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.32
$11.62
50-Day Range
$10.12
$12.32
52-Week Range
$3.00
$13.66
Volume
115,376 shs
Average Volume
234,546 shs
Market Capitalization
$153.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Merrimack Reports Third Quarter 2022 Financial Results
Merrimack Pharmaceuticals (NASDAQ: MACK)
Merrimack Pharmaceuticals: Out For Now
Merrimack Pharmaceuticals GAAP EPS of -$0.01
Merrimack Reports Full Year 2021 Financial Results
Merrimack Pharmaceuticals reports FY results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-2,450,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.06 per share

Miscellaneous

Free Float
9,950,000
Market Cap
$153.54 million
Optionable
Optionable
Beta
1.88

Social Links


Key Executives

  • Mr. Gary L. Crocker M.B.A.Mr. Gary L. Crocker M.B.A. (Age 70)
    MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
    Comp: $105.44k
  • Dr. Ulrik B. Nielsen Ph.D. (Age 50)
    Co-Founder & Independent Director
    Comp: $102.76k
  • Dr. Anthony J. Sinskey Ph.D. (Age 82)
    Sc.D., Co-Founder and Scientific Advisor
  • Geoffrey Grande C.F.A.
    Sr. Director of Communications
  • Ms. Ellen K. Forest (Age 58)
    Head of HR
  • Dr. Fazal R. Khan Ph.D. (Age 72)
    Sr. VP of Manufacturing
  • Dr. Daryl C. Drummond Ph.D. (Age 53)
    Head of Research
  • Mr. Timothy R. Surgenor (Age 62)
    Sec.













MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2023?

Merrimack Pharmaceuticals' stock was trading at $11.46 on January 1st, 2023. Since then, MACK stock has decreased by 0.1% and is now trading at $11.45.
View the best growth stocks for 2023 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $11.45.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $153.54 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 1/29/2023 by MarketBeat.com Staff